1. China Stocks

  2. •

    Health technology

  3. •

    Medical specialties
Suzhou Basecare Medical Corp. Ltd. Class H

Suzhou Basecare Medical Corp. Ltd. Class H

HHKEX:2170
1.34
HKD
-0.03
(-2.55%)
508.76MMarket Cap
Apr 01Next Earn
Suzhou Basecare Medical Corp. Ltd. Class H
HKEX:2170
(Hong Kong Exchange)

Recent

price

1.34

P/E

ratio

- -

div

yld

- -

ROIC.AI

2018
2019
2020
2021
2022
2023
2024
2025
TTM
CNY
0.12
0.21
0.3
0.4
0.52
0.76
1.09
0.85
- -
Revenue per Share
-0.58
-1.99
-3.29
-0.54
-0.45
-0.7
-0.87
-0.82
- -
Basic EPS, GAAP
-0.12
-0.15
-0.27
-0.88
-1.16
-1.36
-1.18
-0.93
- -
Free Cash Flow per Basic Share
- -
- -
- -
- -
- -
- -
- -
- -
- -
Dividend per Share
-1.53
-3.52
1.06
6.27
5.82
5.12
4.18
3.42
3.42
Book Value per Share
-1.53
-3.52
1.06
6.24
5.79
4.11
3.29
2.53
2.53
Tangible Book Value per Share
267
267
267
265
274
274
274
274
274
Basic Weighted Avg Shares
33
56
81
107
141
208
299
233
- -
Sales/Revenue/Turnover
-162.25
-18.43
-67.51
-125.65
-154.91
-117.03
-89.88
-90.76
- -
Operating Margin (%)
8
8
7
6
8
20
36
48
- -
Depreciation Expense
-155
-531
-877
-144
-123
-192
-237
-223
- -
Net Income, GAAP
- -
- -
- -
- -
- -
- -
- -
- -
- -
Effective Tax Rate (%)
-474.95
-954.18
-1,081.33
-134.28
-87.06
-92.17
-79.25
-95.79
- -
Profit Margin (%)
54
63
242
1,642
1,413
1,020
785
567
567
Working Capital
3
1
1
26
73
267
300
289
289
LT Debt
-412
-946
281
1,715
1,592
1,398
1,142
935
935
Total Equity
- -
- -
- -
- -
- -
- -
- -
- -
- -
Return on Invested Capital (%)
- -
- -
- -
- -
- -
- -
- -
- -
- -
Return on Capital (%)
- -
- -
- -
-14.43
-7.42
-12.81
-18.65
-21.51
- -
Return on Common Equity (%)

Capital Structure

CNY

•

in mil. unless spec.
Dec'24
Jun'25
Dec'25
ST Debt
29
37
54
LT Borrowings
296
304
289
LT Finance Leases
3
1
1
Preferred Equity and Hybrid Capital
- -
- -
- -
Shares Outstanding
274
274
274
Market Capitalization
704
706
457

Working Capital

CNY

•

in mil. unless spec.
Dec'24
Jun'25
Dec'25
Total Current Assets
979
865
757
Cash, Cash Equivalents & STI
685
544
443
Accounts Receivable, Net
165
164
174
Inventories
92
124
101
Total Current Liabilities
195
198
190
Payables & Accruals
- -
- -
- -
ST Debt
29
37
54
Deferred Revenue
- -
- -
- -

Growth Rates

CNY

•

in mil. unless spec.

(avg. rate of change)

10 years
5 years
1 year
Total Equity
- -
90.76%
-18.14%
Free Cash Flow
- -
48.39%
-21.39%
Net Income, GAAP
- -
-4.85%
-5.73%
Sales/Revenue/Turnover
- -
26.6%
-22.01%
Total Cash Common Dividend
- -
- -
- -

Semi-annual Revenue

CNY

•

in mil. unless spec.

Year

H1
H2
FY
2023
- -
- -
208
2024
- -
- -
299
2025
- -
- -
233

Semi-annual Earnings Per Share

CNY

•

in mil. unless spec.

Year

H1
H2
FY
2023
- -
- -
-0.7
2024
- -
- -
-0.87
2025
- -
- -
-0.82

Semi-annual Dividends Per Share

CNY

•

in mil. unless spec.

Year

H1
H2
FY
2023
- -
- -
- -
2024
- -
- -
- -
2025
- -
- -
- -
Similar Companies
Intuitive Surgical, Inc. (NASDAQ:ISRG)
Boston Scientific Corporation (NYSE:BSX)
Thermo Fisher Scientific Inc (NYSE:TMO)
Illumina, Inc. (NASDAQ:ILMN)
Abbott Laboratories (NYSE:ABT)
GRAIL, Inc. (NASDAQ:GRAL)
Business
Suzhou Basecare Medical Corporation Limited (2170.HK) is a biotechnology company specializing in genomic testing and precision medicine solutions for oncology and rare diseases. The company develops and offers clinical genetic testing services, including next-generation sequencing (NGS) panels such as tumor genomic profiling, hereditary cancer screening, and non-invasive prenatal testing (NIPT); companion diagnostic services for targeted therapies; and bioinformatics platforms for data analysis and interpretation. Basecare provides these offerings through its proprietary BasecareMDx brand and operates primarily in China, with expanding presence in Asia-Pacific regions. Founded in 2012 and headquartered in Suzhou, China, the company serves hospitals, clinics, and pharmaceutical partners in the healthcare sector. In recent developments, Basecare announced a strategic partnership with a leading international pharmaceutical firm in 2024 to co-develop companion diagnostics for novel cancer therapies, alongside securing a Series D funding round exceeding RMB 500 million to fuel expansion into Southeast Asia and enhance its AI-driven genomic analytics platform.